Tolerance of high‐dose (3,000 mg/day) coenzyme Q10 in ALS
Abstract
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Plasma CoQ10 levels reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage in PD, HD or ALS patients.
“However, plasma CoQ10 levels reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage in PD, HD or ALS patients161, 162.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [162]
Cites
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,126 · see citing works
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · see citing works
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223 · see citing works
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
Cudkowicz, M., Shefner, J. M., Schoenfeld, D., Brown, R. H., Jr., Johnson, H., Qureshi, M., Jacobs, M., Rothstein, J. D., Appel, S. H., Pascuzzi, R. M., et al. (2003) · Neurology · doi:10.1212/wnl.61.4.456 · Cited by 203 · see citing works
Self-citationAssay of Coenzyme Q10 in Plasma by a Single Dilution Step
Mosca, F., Fattorini, D., Bompadre, S., et al. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5653 · Cited by 134 · see citing works
Ibrahim, W. H., Chow, C. K., Bhagavan, H. N., & Chopra, R. K. (2000) · Journal of Nutrition · doi:10.1093/jn/130.9.2343 · Cited by 90 · see citing works
Mitochondria and the pathogenesis of ALS
Beal, M. F. (2000) · Brain · doi:10.1093/brain/123.7.1291 · Cited by 80 · see citing works
Self-citationBeal, M. F., & Matthews, R. T. (1997) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(97)00024-1 · Cited by 58 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451 · see citing works
NADPH oxidase in brain injury and neurodegenerative disorders
Ma, M. W., Wang, J., Zhang, Q., Wang, R., Dhandapani, K. M., Vadlamudi, R. K., & Brann, D. W. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0150-7 · Cited by 432 · see citing works
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · see citing works
Self-citationPlasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations
Bhagavan, H. N., & Chopra, R. K. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.003 · Cited by 243 · see citing works
Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156 · see citing works
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127 · see citing works
Risk assessment for coenzyme Q10 (Ubiquinone)
Hathcock, J. N., & Shao, A. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.05.006 · Cited by 114 · see citing works
Yang, X., Yang, Y., Li, G., Wang, J., & Yang, E. S. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9033-7 · Cited by 111 · see citing works
The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease
Haas, R. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.008 · Cited by 92 · see citing works
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89 · see citing works
Shetty, R. A., Forster, M. J., & Sumien, N. (2013) · AGE · doi:10.1007/s11357-012-9484-9 · Cited by 47 · see citing works
Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice
Sumien, N., Heinrich, K. R., Shetty, R. A., Sohal, R. S., & Forster, M. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.110437 · Cited by 46 · see citing works
- Authors
- Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., Newhall, K., Donofrio, P., Caress, J., Ashburn, C., Freiberg, B., O'Neill, C., Paladenech, C., Walker, T., Pestronk, A., Abrams, B., Florence, J., Renna, R., Schierbecker, J., Malkus, B., & Cudkowicz, M.
- Affiliations
- Harvard University (US)
- From Neurology Clinical Trials Unit (Drs. Traynor and Cudkowicz, K.L., Ferrante, M. O'Brien, Y. Yu, M. Fantasia, K. Newhall), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology (Dr. Shefner and J. Taft), SUNY Upstate Medical University, Syracuse, NY; Department of Biostatistics (Dr. Betensky and H. Zhang), Massachusetts General Hospital Biostatistics Center, Harvard Medical School, Boston; Department of Neurology and Neuroscience (Dr. Beal), Weill Medical College...
- ORCID
- Venue
- Neurology
- Published
- 2005-12-13
- Volume
- 65
- Issue
- 11
- Pages
- 1834-1836
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2160912479
- Cited by
- 154
- References
- 8
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 2 · 2022: 9 · 2021: 4 · 2020: 5 · 2019: 3 · 2018: 1 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 4 · 2013: 6 · 2012: 8
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Muscular Dystrophy Association
- National Center for Research Resources (M01RR001066, M01RR007122, M01RR000036)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- coenzyme Q10, amyotrophic lateral sclerosis, high-dose supplementation, safety and tolerability, mitochondrial dysfunction, dose escalation
- MeSH terms
- Amyotrophic Lateral Sclerosis, Central Nervous System, Coenzymes, Dose-Response Relationship, Drug, Drug Tolerance, Energy Metabolism, Female, Humans, Male, Middle Aged, Mitochondria, Nerve Degeneration, Neurons, Ubiquinone, Free Radical Scavengers, Neuroprotective Agents, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
